SCHEMBL4704082

SCHEMBL4704082

NC[CH]c1cccc(NC(=O)N2CCN(C(N)=O)CC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.50
MAPT P10636 3/20 0.48
USP2 O75604 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HTT P42858 2/20 0.48
HCRTR1 O43613 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
MAPK1 P28482 1/20 0.48
CYP2C19 P33261 1/20 0.48
LMNA P02545 3/20 0.47
FAAH O00519 2/20 0.46
ALDH1A1 P00352 2/20 0.46
RECQL P46063 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
KDM4E B2RXH2 2/20 0.45
RAB9A P51151 2/20 0.45
CA12 O43570 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4705980 0.76 GPR35 (0.43) POLBMAPTMEN1KMT2AHTT
SCHEMBL28336995 0.75 POLB (0.75) POLBMAPTUSP2MEN1KMT2A
SCHEMBL5244156 0.71 F2 (0.46) POLBMAPTMEN1KMT2AHTT
SCHEMBL3647854 0.69 KDM4E (0.65) POLBMAPTUSP2MEN1KMT2A
SCHEMBL4999588 0.69 KMT2A (0.62) POLBMAPTUSP2MEN1KMT2A
SCHEMBL4999849 0.69 ALDH1A1 (0.58) POLBMAPTUSP2MEN1KMT2A
SCHEMBL27715771 0.68 KDM4E (0.64) POLBMAPTUSP2MEN1KMT2A
SCHEMBL28273734 0.68 MEN1 (0.88) POLBMAPTUSP2MEN1KMT2A
SCHEMBL11145852 0.68 ALDH1A1 (0.88) POLBMAPTUSP2MEN1KMT2A
SCHEMBL8868089 0.68 NPC1 (0.58) POLBMAPTUSP2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1871776-A2 FUSED THIENO[2,3-B]PYRIDINE AND THIAZOLO[5,4-B]PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2008-01-02 EP disclosed
US-20060247320-A1 Compounds for inhibiting KSP kinesin activity SCHERING CORPORATION 2006-11-02 US disclosed
WO-2006098961-A2 FUSED THIENO [2, 3-B] PYRIDINE AND THIAZOLO [5, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247320-A1 Compounds for inhibiting KSP kinesin activity KIFC1, KIF5B, KIF2C POLB 859/4885MAPT 434/4885USP2 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.